Excipients used in nano-technology assisted drug delivery systems

Journal of Excipients and Food Chemicals

Volumn 5, Issue 4, 2014, Pages 173-176

  Bansal, Arvind Kumar ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Drug delivery; Excipients; NADDS; Nano technology; Regulatory expectations

Indexed keywords

EXCIPIENT; POLYMER; SOLID LIPID NANOPARTICLE; STABILIZING AGENT;

DRUG CONTROL; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; EDITORIAL; EMULSION; EXCIPIENT COMPATIBILITY; MOLECULAR SIZE; NANOENGINEERING; NANOTECHNOLOGY; NANOTECHNOLOGY ASSISTED DRUG DELIVERY SYSTEM; PARTICLE SIZE; PHYSICAL CHEMISTRY;

EID: 84919446167     PISSN: None     EISSN: 21502668     Source Type: Journal    
DOI: None     Document Type: Editorial

References (6)

1. National nanotechnology Initiative Strategic plan, National Science and Technology Council Committee on Technology Subcommittee on Nanoscale Science, Engineering, and Technology, Executive Office of the President of the United States, February 2014.
2. Desai N, (2012). Challenges in development of nanoparticle-based therapeutics, AAPS J 14 (2):282–295.
3. Guidance for industry: Considering Whether an FDARegulated Product Involves the Application of Nanotechnology, US FDA, U.S. Department of Health and Human Services, June 2014.
4. European Pharmacopoeia, Seventh edition (7.0) 2012.5 15. Functionality-Related Characteristics of Excipients, 661-662
5. Moreton C, (2010), Trends in Pharmaceutical Excipients: An Update, Am. Pharm. Rev., 13 (6), 22–27.
6. Draft Guidance for Industry: Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients That Are Color Additives; Availability, US FDA, U.S. Department of Health and Human Services, April, 2012.